Price Alert

Schrödinger Inc. (SDGR)

NASDAQ: SDGR · Real-Time Price · USD

18.91

-0.54 (-2.78%)

At close: Aug 15, 2025, 12:50 PM

-2.78% (1D)

Bid	18.91
Market Cap	1.39B
Revenue (ttm)	237.92M
Net Income (ttm)	-181.33M
EPS (ttm)	-2.48
PE Ratio (ttm)	-7.63
Forward PE	-9.83
Analyst	Buy

Ask	18.94
Volume	1,173,232
Avg. Volume (20D)	1,222,243
Open	18.66
Previous Close	19.45
Day's Range	18.11 - 19.09
52-Week Range	16.60 - 28.47
Beta	1.68

About SDGR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SDGR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SDGR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Schrödinger has released their quartely earnings on Aug 6, 2025:

Revenue of $54.76M exceeds estimates by $2.73M, with 15.69% YoY growth.

EPS of -0.65 exceeds estimates by 0.07, with 1.52% YoY growth.

Next Earnings Release

Schrödinger Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

-1.97%

Schrodinger shares are trading lower after the com... Unlock content with Pro Subscription

2 months ago

-14.42%

Schrodinger shares are trading lower. The company announced initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies.

News

23 hours ago · businesswire.com

Schrödinger Announces Discontinuation of SGR-2921 Program

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Pha...

1 week ago · seekingalpha.com

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Karen...

1 week ago · zacks.com

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.74 per share a year ago.

1 week ago · fool.com

Schrödinger (SDGR) Q2 2025 Earnings Transcript

Image source: The Motley Fool.

1 week ago · businesswire.com

Schrödinger Reports Second Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.

2 weeks ago · businesswire.com

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a con...

3 weeks ago · zacks.com

Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · businesswire.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 14, 2025, the company granted restricted stock units (RSUs) with respect to 3,488 shares of the company's common...

4 weeks ago · businesswire.com

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus...

1 month ago · businesswire.com

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administ...

Load More News